GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chembio Diagnostics Inc (NAS:CEMI) » Definitions » Beneish M-Score

Chembio Diagnostics (Chembio Diagnostics) Beneish M-Score : -3.53 (As of Apr. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Chembio Diagnostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.53 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Chembio Diagnostics's Beneish M-Score or its related term are showing as below:

CEMI' s Beneish M-Score Range Over the Past 10 Years
Min: -4.09   Med: -1.99   Max: 3.29
Current: -3.53

During the past 13 years, the highest Beneish M-Score of Chembio Diagnostics was 3.29. The lowest was -4.09. And the median was -1.99.


Chembio Diagnostics Beneish M-Score Historical Data

The historical data trend for Chembio Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chembio Diagnostics Beneish M-Score Chart

Chembio Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -4.09 -2.82 0.57 -3.53

Chembio Diagnostics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 -0.16 -2.03 -2.77 -3.53

Competitive Comparison of Chembio Diagnostics's Beneish M-Score

For the Diagnostics & Research subindustry, Chembio Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chembio Diagnostics's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chembio Diagnostics's Beneish M-Score falls into.



Chembio Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chembio Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2501+0.528 * 0.326+0.404 * 0.1348+0.892 * 1.3091+0.115 * 1.0632
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7466+4.679 * -0.168581-0.327 * 1.3448
=-3.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Total Receivables was $18.72 Mil.
Revenue was 9.162 + 11.2 + 9.161 + 18.817 = $48.34 Mil.
Gross Profit was 3.553 + 1.541 + 1.075 + 3.593 = $9.76 Mil.
Total Current Assets was $48.45 Mil.
Total Assets was $62.61 Mil.
Property, Plant and Equipment(Net PPE) was $13.73 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.55 Mil.
Selling, General, & Admin. Expense(SGA) was $24.28 Mil.
Total Current Liabilities was $39.30 Mil.
Long-Term Debt & Capital Lease Obligation was $5.51 Mil.
Net Income was -0.855 + -6.699 + -6.946 + -8.79 = $-23.29 Mil.
Non Operating Income was 3.112 + -0.11 + 0 + -3.043 = $-0.04 Mil.
Cash Flow from Operations was -2.832 + -5.06 + -0.433 + -4.369 = $-12.69 Mil.
Total Receivables was $11.44 Mil.
Revenue was 17.712 + 9.658 + 4.182 + 5.374 = $36.93 Mil.
Gross Profit was -1.293 + 1.756 + 0.142 + 1.826 = $2.43 Mil.
Total Current Assets was $54.85 Mil.
Total Assets was $73.25 Mil.
Property, Plant and Equipment(Net PPE) was $14.64 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.93 Mil.
Selling, General, & Admin. Expense(SGA) was $24.84 Mil.
Total Current Liabilities was $15.28 Mil.
Long-Term Debt & Capital Lease Obligation was $23.71 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18.723 / 48.34) / (11.441 / 36.926)
=0.387319 / 0.309836
=1.2501

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.431 / 36.926) / (9.762 / 48.34)
=0.065834 / 0.201945
=0.326

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (48.452 + 13.725) / 62.611) / (1 - (54.845 + 14.641) / 73.252)
=0.006932 / 0.051412
=0.1348

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=48.34 / 36.926
=1.3091

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.931 / (2.931 + 14.641)) / (2.554 / (2.554 + 13.725))
=0.166799 / 0.156889
=1.0632

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(24.277 / 48.34) / (24.84 / 36.926)
=0.502213 / 0.672697
=0.7466

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.513 + 39.3) / 62.611) / ((23.705 + 15.282) / 73.252)
=0.715737 / 0.532231
=1.3448

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-23.29 - -0.041 - -12.694) / 62.611
=-0.168581

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Chembio Diagnostics has a M-score of -3.53 suggests that the company is unlikely to be a manipulator.


Chembio Diagnostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Chembio Diagnostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Chembio Diagnostics (Chembio Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3661 Horseblock Road, Medford, NY, USA, 11763
Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
Executives
Perceptive Credit Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Leslie Teso-lichtman director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Charles Caso officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Paul Angelico officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Lawrence J. Steenvoorden officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
David William Bespalko director 29 CEDAR DRIVE, ALLENDALE NJ 07401
David Acheson director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Richard Eberly officer: See Remarks 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John Gary Potthoff director 6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738
Javan Esfandiari officer: Senior Vice President 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Robert Passas officer: See Remarks 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Polan Mary Lake Ph D director STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317
Neil A Goldman officer: Executive VP and CFO 3661 HORSEBLOCK RD, MEDFORD NY 11763